USE OF THERAPEUTIC DRUG MONITORING (TDM) TO OPTIMISE ORAL/ENTERAL HYDROXYCHLOROQUINE DOSING IN CRITICALLY ILL PATIENTS WITH COVID-19
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA85495
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$117,313.8Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
Queensland University of TechnologyResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Supportive care, processes of care and managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
The Royal Brisbane and Women's Hospital Intensive Care Unit Clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all Covid-19 patients admitted to the ICU should receive hydroxychloroquine as standard of care. This study is to determine whether therapeutic drug monitoring of hydroxychloroquine dosing in Covid-19 patients results in clinically significant alterations in the drug dosing regimen.